Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.43 |
| ▸ | FLT3 | P36888 | 7/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030180 | 0.87 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA3KDR | |
| SCHEMBL3034596 | 0.86 | FLT3 (0.51) | GABRA1GABRG2GABRB3GABRA3KDR | |
| SCHEMBL3033329 | 0.83 | KDR (0.51) | GABRG2GABRB3GABRA3KDRFGFR3 | |
| SCHEMBL3025605 | 0.82 | KDR (0.57) | GABRA1GABRG2GABRB3GABRA3KDR | |
| SCHEMBL3653316 | 0.80 | FLT3 (0.56) | FLT3 | |
| SCHEMBL3026044 | 0.78 | KDR (0.54) | GABRG2GABRB3GABRA3KDRFGFR3 | |
| SCHEMBL3026012 | 0.77 | KDR (0.55) | GABRG2GABRB3GABRA3KDRFGFR3 | |
| SCHEMBL3033053 | 0.77 | FLT3 (0.45) | GABRA1GABRG2GABRB3GABRA3KDR | |
| SCHEMBL3014290 | 0.76 | KDR (0.52) | GABRG2GABRB3GABRA3KDRFGFR3 | |
| SCHEMBL3025888 | 0.76 | FGFR3 (0.49) | KDRFGFR3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | GABRA1 1263/4885GABRG2 2020/4885GABRB3 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.